Description
The Expert noted that senolytics lack validated biomarkers for in vivo target engagement, making clinical development nearly impossible. This represents a critical translational bottleneck for all senescence-based neurotherapies discussed.
Source: Debate session sess_SDA-2026-04-02-gap-senescent-clearance-neuro (Analysis: SDA-2026-04-02-gap-senescent-clearance-neuro)